These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21613463)

  • 1. Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.
    Lafer MM; Weckx LY; de Moraes-Pinto MI; Garretson A; Steinberg SP; Gershon AA; LaRussa PS
    Clin Vaccine Immunol; 2011 Jul; 18(7):1194-7. PubMed ID: 21613463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The differences in short- and long-term varicella-zoster virus (VZV) immunoglobulin G levels following varicella vaccination of healthcare workers measured by VZV fluorescent-antibody-to-membrane-antigen assay (FAMA), VZV time-resolved fluorescence immunoassay and a VZV purified glycoprotein enzyme immunoassay.
    Maple PA; Haedicke J; Quinlivan M; Steinberg SP; Gershon AA; Brown KE; Breuer J
    Epidemiol Infect; 2016 Aug; 144(11):2345-53. PubMed ID: 27018820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test.
    Sauerbrei A; Färber I; Brandstädt A; Schacke M; Wutzler P
    J Virol Methods; 2004 Jul; 119(1):25-30. PubMed ID: 15109817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of antibodies to varicella-zoster virus using a virus-free fluorescent-antibody-to-membrane-antigen (FAMA) test.
    Park R; Hwang JY; Lee KI; Namkoong S; Choi SK; Park S; Park H; Park J
    J Microbiol Biotechnol; 2015 Feb; 25(2):268-73. PubMed ID: 25248983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test.
    Sauerbrei A; Schäfler A; Hofmann J; Schacke M; Gruhn B; Wutzler P
    Clin Vaccine Immunol; 2012 Aug; 19(8):1261-8. PubMed ID: 22718131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of varicella-zoster virus (VZV) fluorescent-antibody-to-membrane-antigen (FAMA) testing on sensitivity of determining VZV immunity in healthcare workers and on furlough days.
    Rolando L; Schneider WJ; Steinberg S; Low S; Stiles J; Gomez L; Gershon AA; Brown AE
    Infect Control Hosp Epidemiol; 2010 Sep; 31(9):972-4. PubMed ID: 20666603
    [No Abstract]   [Full Text] [Related]  

  • 7. Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.
    Sauerbrei A; Wutzler P
    J Clin Microbiol; 2006 Sep; 44(9):3094-7. PubMed ID: 16954232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany.
    Wiese-Posselt M; Siedler A; Mankertz A; Sauerbrei A; Hengel H; Wichmann O; Poethko-Müller C
    BMC Infect Dis; 2017 May; 17(1):356. PubMed ID: 28525973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Seroepidemiology of varicella-zoster virus infection measured by the fluorescent antibody to membrane antigen test].
    Liu JJ; Wang ML; Gan L; Liao WJ; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Apr; 30(4):371-5. PubMed ID: 19731531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of varicella-zoster virus as measured by fluorescent antibody to membrane antigen assay and glycoprotein enzyme-linked immunosorbent assay more than 10 years after initiation of a universal vaccination program: An observational study.
    Ji HS; Kang KR; Kang HM; Choi UY; Lee SY; Kang JH
    Medicine (Baltimore); 2024 Jan; 103(3):e36931. PubMed ID: 38241578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of anticomplement immunofluorescence and fluorescent antibody-to-membrane antigen tests for determination of immunity status to varicella-zoster virus and for serodifferentiation of varicella-zoster and herpes simplex virus infections.
    Gallo D; Schmidt NJ
    J Clin Microbiol; 1981 Nov; 14(5):539-43. PubMed ID: 6273453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus.
    Landry ML; Cohen SD; Mayo DR; Fong CK; Andiman WA
    J Clin Microbiol; 1987 May; 25(5):832-5. PubMed ID: 3034966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance characteristics of a quantitative, standardised varicella zoster IgG time resolved fluorescence immunoassay (VZV TRFIA) for measuring antibody following natural infection.
    Chris Maple PA; Gray J; Brown K; Brown D
    J Virol Methods; 2009 Apr; 157(1):90-2. PubMed ID: 19135089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay.
    Liu J; Chen C; Zhu R; Ye X; Jia J; Yang L; Wang Y; Wang W; Ye J; Li Y; Zhu H; Zhao Q; Zhang J; Cheng T; Xia N
    Appl Microbiol Biotechnol; 2016 Nov; 100(21):9321-9329. PubMed ID: 27629124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody responses to early antigens of varicella-zoster virus (VZV) during varicella and zoster.
    Namazue J; Kato T; Yamanishi K; Takahashi M; Asano Y; Muraki R
    Biken J; 1986 Dec; 29(3-4):91-7. PubMed ID: 3039973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simplified immunofluorescence technique for antibody to varicella-zoster membrane antigen (FAMA).
    Baba K; Yoshida M; Tawa A; Yabuuchi H; Maeda K; Takahashi M
    Biken J; 1984 Mar; 27(1):23-9. PubMed ID: 6091617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus.
    Shanley J; Myers M; Edmond B; Steele R
    J Clin Microbiol; 1982 Feb; 15(2):208-11. PubMed ID: 6279689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement-enhanced neutralizing antibody response to varicella-zoster virus.
    Grose C; Edmond BJ; Brunell PA
    J Infect Dis; 1979 Apr; 139(4):432-7. PubMed ID: 220336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of varicella-zoster virus immunoglobulin G antibodies in Swiss adolescents and risk factor analysis for seronegativity.
    Heininger U; Braun-Fahrländer C; Desgrandchamps D; Glaus J; Grize L; Wutzler P; Schaad UB;
    Pediatr Infect Dis J; 2001 Aug; 20(8):775-8. PubMed ID: 11734740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and specificity of different antibody tests for detecting varicella-zoster virus.
    Otani N; Shima M; Tanimura S; Ueda T; Ichiki K; Nakajima K; Takesue Y; Honjo K; Okuno T
    J Infect Chemother; 2020 Dec; 26(12):1283-1287. PubMed ID: 32843302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.